Navigation Links
Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
Date:4/28/2011

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID™ Phase 3 trials will be presented at the following medical meetings:Digestive Disease Week (DDW), McCormick Place, Chicago, ILMay 7-10, 2011Poster Presentation Information:Title:

Risk of Recurrence and Time to Recurrence Following Treatment of Clostridium difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin vs. VancomycinPresenter:

Kathleen M. Mullane, D.O.Date:

Saturday, May 7, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Intestinal Disorders: Prebiotics, Probiotics and PathogensProgram #:

Sa1981Poster Presentation Information:Title:

High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 inPatients with C. difficile infection:  Combined Results of Two Phase 3 TrialsPresenter:

Pamela S. Sears, Ph.D. Date:

Monday, May 9, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Randomized Controlled Clinical TrialsProgram #:

Mo1160European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milano Convention Center, Milan, ItalyMay 7-10, 2011 Oral Presentation Information:Title:

Immunosuppression and the Risk of Death, Cure Rates and Disease RecurrenceAmong Patients with Clostridium difficile InfectionPresenter:

Yoav Golan, M.D., M.S.Date:

Tuesday, May 10, 2011 Time:

10:36 a.m. to 10:48 a.m. Central European TimeLocation:

Lecture Hall Brown 1Oral Session:

C. difficile NewsPresentation #:

O504Poster Presentation Information:Title:

Cl
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- Research and Markets  has announced the addition ... Services, End-User , Application - Global Forecast to 2019" ... global oligonucleotide synthesis market is expected to reach $1,712.1 ... at a CAGR of 9.8% from 2014 to 2019. ... basis of products and services, applications, end users, and ...
(Date:9/29/2014)... batteries are efficient but involve a range of ... (lucerne seed) and pine resin and a clever ... with a highly interesting alternative. Their study will ... ChemSusChem . , ,We think our discovery can ... for the batteries of the future, says Daniel ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... Burnham Securities Inc. ("Burnham"), a financial ... leader in healthcare venture development and strategic transactions ... expand the range of services each company can ... Securities will be supported by a team of ... in healthcare industry to build a healthcare franchise. ...
Breaking Biology Technology:Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Smart, eco-friendly new battery to solve problems 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... MA (July 20, 2011)A consortium led by scientists at the ... world,s most detailed genetic map. A genetic map ... sperm or egg where the DNA from the mother and ... reproductive cell. The biological process whereby this reshuffling occurs is ...
... (Nasdaq: SGMO ) today announced that the company ... July 27, 2011, after the market closes. The press release ... ET, which will be open to the public via telephone ... the financial results and discuss other business matters. ...
... July 20, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. ... its microRNA alliance with GSK, which is focused on ...
Cached Biology Technology:Researchers create the world's most advanced genetic map 2Researchers create the world's most advanced genetic map 3Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4
(Date:9/29/2014)... significant anti-tumour activity in patients with advanced BRAF ... has progressed after chemotherapy, according to phase II ... Madrid, Spain. , "Reports of lung cancers ... because these mutations may be associated with increased ... author Dr David Planchard, pulmonary oncologist at the ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... 26, 2012   Reportlinker.com announces that a ... its catalogue: Biometrics Market ... TechNavio,s analysts forecast the ... a CAGR of 42.4 percent over the ...
... University of Massachusetts Amherst resource economist Sylvia Brandt, with colleagues ... upward for childhood asthma and for the first time include ... study released this week in the early online version of ... of asthma due to pollution is much higher than past ...
... The Department of Energy,s Pacific Northwest National Laboratory ... that improves research sample analysis to the marketplace. ... PNNL is receiving a 2012 award for Excellence ... network that encourages federal laboratories to transfer lab-developed ...
Cached Biology News:Biometrics Market in India 2010 - 2014 2Asthma rate and costs from traffic-related air pollution are much higher than once believed 2PNNL recognized for technology transfer 2
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... II (Dual-Stage Quadrupole) Thermo Scientific (Part ... in analytical instrumentation, introduces the latest product ... II. Based on the proven reliability and ... GC/MS systems, the DSQ II incorporates the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: